title: Proteasome inhibitor drugs on the rise.
abstract: In May 2003, the U.S. Food and Drug Administration granted the proteasome inhibitor bortezomib (Velcade) fast-track status for the treatment of multiple myeloma. This landmark represented the first approval of a drug targeting the ubiquitin-proteasome system (UPS) for any indication. More recently, at the AACR Special Conference "Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic" (Orlando, FL, January 18-22, 2006), it became evident that drug discovery in the UPS is experiencing another round of great excitement. The reason--new clinical applications found for bortezomib, along with the promised success of new types of proteasome inhibitors reaching the clinic.
authors.affiliation: Genomics Institute of the Novartis Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA. cjoazeiro@hotmail.com
authors.forename: Claudio A P
authors.initials: CA
authors.lastname: Joazeiro
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Tony
authors.initials: T
authors.lastname: Hunter
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use; D025801:Ubiquitin / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D025801:Ubiquitin; D000069286:Bortezomib